VNRX VolitionRx Ltd: Year-over-year earnings per share growth for the last twelve months

Graphic logo of VolitionRx (VNRX)

The Nu.Q epigenetic testing ecosystem for veterinary check-ups provides a stable B2B stream, which impacts the quarterly EPS dynamics for VolitionRx Limited (VNRX). This metric is 79.80. Revenue growth is based on liquid biopsy for animal and human diagnostics; however, the project's success relies on physician adoption of the methodology, insurance coverage, and FDA regulatory approval.

VNRX: VolitionRx Earnings per share growth in annualized terms for the last twelve months 07/04/2022 - 11/15/2026

Summary analytical data breakdowns for VolitionRx (VNRX)

- share price and expert price forecast:
Stock Price VolitionRx|VNRX - Analyst Consensus Forecast
- company stock capitalization data:
Market Value VolitionRx|VNRX - Total Company Value
- book capitalization data:
Accounting Value per Share VolitionRx|VNRX - Total Stockholders' Equity|Market Value to Book Value Ratio volition.com|VNRX - Company Total Asset Base
- debt burden and liquidity indicators:
Total Debt to Capital VolitionRx Limited|VNRX - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity VolitionRx Limited|VNRX - Company Total Debt Obligations|Debt to Book Value VolitionRx|VNRX - Company Long-Term Debt|Company Short-Term Debt VolitionRx|Quick Liquidity volition.com
- earnings and valuation multiples information:
VNRX - Company Net Income|Projected Future Earnings VolitionRx Limited|VNRX - Business Payback Period|Projected Price to Earnings volition.com|VNRX - Company Value to Earnings Growth Ratio|EV/EBITDA Multiple VolitionRx Ltd.|VNRX - Operating income before deduction of amortization|Earnings per share for the last twelve months VolitionRx|VNRX - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months volition.com|VNRX - Earnings per share growth this year|Net earnings per share growth forecast for next year VolitionRx Limited
- sales volume and revenue indicators:
VNRX - Company Sales Revenue|Company Future Sales Volume VolitionRx Limited|VNRX - Market Cap to Revenue Ratio|Forward Price-to-Revenue Multiple VolitionRx Limited|VNRX - Revenue Dynamics YoY (Last Twelve Months)
Analysis of all company metrics:VolitionRx Limited, VNRX
Flagship merchandise of volition.com

VolitionRx Limited (VNRX) operates within a sovereign commercialization cycle for oncology diagnostics, where financial performance depends on the adoption rate of tests in laboratories. This indicator digitizes the rate of change in quarterly earnings per share, allowing for the identification of a fundamental reversal prior to market shocks, while the quarterly EPS growth trend signals either momentum strength or the risk of a deep correction.

Direct competitors

Caris (CAI) - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months Guardant Corp (GH)|Year-over-year earnings per share growth for the last twelve months Veracyte, Inc.|Year-over-year earnings per share growth for the last twelve months CELC|Year-over-year net earnings per share growth for the last 12 months GRAL (GRAIL Bio)|MYGN - Earnings per share growth in annualized terms for the last twelve months|Year-over-year earnings per share growth for the last twelve months Castle Bio CSTL|Year-over-year net earnings per share change for the last twelve months Burning Rock Biotech Ltd (BNR)|biodesix.com - Quarterly EPS earnings growth|Year-over-year net earnings per share change for the last twelve months precipiodx.com PRPO|Check-Cap Ltd. (CHEK) - Year-over-year earnings per share growth for the last twelve months|MYNZ - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months OncoCyte Corporation